DT-13 ameliorates LPS-induced acute lung injury via targeting NMMHC IIA to modulate the FOXO1/KLF2/SPHK1 pathway

Abstract

The pathogenesis of acute lung injury (ALI) and the severe form of ALI, acute respiratory distress syndrome (ARDS), is incompletely understood. We aimed to determine the mechanism of action for non-muscle myosin heavy-chain IIA (NMMHC IIA) and the NMMHC IIA targeting compound in the context of lipopolysaccharide (LPS)-induced pulmonary endothelial barrier dysfunction associated with ALI. Endothelial-specific monoallelic knockout of NMMHC IIA alleviated ALI and reversed alterations in sphingosine-1-phosphate (S1P), a serum metabolite. Inhibition of NMMHC IIA upregulated SPHK1, a key S1P-synthesizing enzyme, and the SPHK1 transcriptional regulator, KLF2. NMMHC IIA directly interacted with FOXO1 in LPS-treated endothelial cells to promote FOXO1 nuclear translocation. Knockdown of MYH9 or FOXO1 restored barrier integrity by activating the KLF2/SPHK1 pathway. Endothelial NMMHC IIA knockdown promoted FOXO1 dephosphorylation and KLF2/SPHK1 activation in vivo, which increased serum S1P levels; NMMHC IIA overexpression exerted opposite effects. Furthermore, DT-13, a steroidal sapogenin derived from Liriope muscari, was confirmed to bind to NMMHC IIA via the cellular thermal shift assay (CETSA) and microscale thermophoresis (MST) assay. DT-13 attenuated LPS-induced endothelial barrier disruption by targeting NMMHC IIA and mediating the FOXO1/KLF2/SPHK1 axis. The findings herein elucidate a new mechanism underlying ALI pathogenesis and suggest promising therapeutic strategies.

Keywords

DT-13 / non-muscle myosin IIA / acute lung injury / metabolomic / FOXO1/KLF2/SPHK1 pathway

References

[1] Wick KD, Aggarwal NR, Curley MAQ, Fowler AA 3rd, Jaber S, Kostrubiec M, et al.: Opportunities for Improved Clinical Trial Designs in Acute Respiratory Distress Syndrome. The Lancet Respiratory Medicine 2022, 10: 916-924.

[2] Beitler JR, Thompson BT, Baron RM, Bastarache JA, Denlinger LC, Esserman L, et al.: Advancing Precision Medicine for Acute Respiratory Distress Syndrome. The Lancet Respiratory Medicine 2022, 10: 107-120.

[3] Matthay MA, Arabi Y, Arroliga AC, Bernard G, Bersten AD, Brochard LJ, et al.: A New Global Definition of Acute Respiratory Distress Syndrome. American Journal of Respiratory and Critical Care Medicine 2024, 209: 37-47.

[4] Sud S, Friedrich JO, Adhikari NKJ, Fan E, Ferguson ND, Guyatt G, et al.: Comparative Effectiveness of Protective Ventilation Strategies for Moderate and Severe Acute Respiratory Distress Syndrome. A Network Meta-Analysis. American Journal of Respiratory and Critical Care Medicine 2021, 203: 1366-1377.

[5] Zhang HH, Kuo WS, Tu PY, Lee CT, Wang HC, Huang YT, et al.: Enhancing Lung Recovery: Inhaled Poly(lactic- co-glycolic) Acid Encapsulating FTY720 and Nobiletin for Lipopolysaccharide-Induced Lung Injury, with Advanced Inhalation Tower Technology . ACS Nano 2025, 19: 7634-7649.

[6] Aslan A, Aslan C, Zolbanin NM, Jafari R: Acute Respiratory Distress Syndrome in COVID-19: Possible Mechanisms and Therapeutic Management. Pneumonia (Nathan Qld) 2021, 13: 14.

[7] Beurton A, Kooistra EJ, De Jong A, Schiffl H, Jourdain M, Garcia B, et al.: Specific and Non-specific Aspects and Future Challenges of ICU Care among COVID-19 Patients with Obesity: A Narrative Review. Current Obesity Reports 2024, 13: 545-563.

[8] Borek I, Birnhuber A, Voelkel NF, Marsh LM, Kwapiszewska G: The Vascular Perspective on Acute and Chronic Lung Disease. The Journal of Clinical Investigation 2023, 133: e170502.

[9] Qiao X, Yin J, Zheng Z, Li L, Feng X: Endothelial Cell Dynamics in Sepsis-induced Acute Lung Injury and Acute Respiratory Distress Syndrome: Pathogenesis and Therapeutic Implications. Cell Communication and Signaling 2024, 22: 241.

[10] Brito C, Sousa S: Non-Muscle Myosin 2A (NM2A): Structure, Regulation and Function. Cells 2020, 9: 1590.

[11] Li P, Wei G, Cao Y, Deng Q, Han X, Huang X, et al.: Myosin IIa is Critical for cAMP-Mediated Endothelial Secretion of von Willebrand Factor. Blood 2018, 131: 686-698.

[12] Gong S, Cao G, Li F, Chen Z, Pan X, Ma H, et al.: Endothelial Conditional Knockdown of NMMHC IIA (Nonmuscle Myosin Heavy Chain IIA) Attenuates Blood-Brain Barrier Damage During Ischemia-Reperfusion Injury. Stroke 2021, 52: 1053-1064.

[13] Wu Y, Yu X, Wang Y, Huang Y, Tang J, Gong S, et al.: Ruscogenin Alleviates LPS-triggered Pulmonary Endothelial Barrier Dysfunction through Targeting NMMHC IIA to Modulate TLR4 Signaling. Acta Pharmaceutica Sinica B 2022, 12: 1198-1212.

[14] Passos FRS, Araújo-Filho HG, Monteiro BS, Shanmugam S, Araújo AAS, Almeida JRGDS, et al.: Anti-inflammatory and Modulatory Effects of Steroidal Saponins and Sapogenins on Cytokines: A Review of Pre-clinical Research. Phytomedicine 2022, 96: 153842.

[15] Wang C, He H, Liu G, Ma H, Li L, Jiang M, et al.: DT-13 Induced Apoptosis and Promoted Differentiation of Acute Myeloid Leukemia Cells by Activating AMPK-KLF2 Pathway. Pharmacological Research 2020, 158: 104864.

[16] Zhang Y, Han Y, Zhao Y, Lv Y, Hu Y, Tan Y, et al.: DT-13 Ameliorates TNF-α-Induced Vascular Endothelial Hyperpermeability via Non-Muscle Myosin IIA and the Src/PI3K/Akt Signaling Pathway. Frontiers in Immunology 2017, 8: 925.

[17] Li YW, Qi J, Zhang YY, Huang Z, Kou JP, Zhou SP, et al.: Novel Cytotoxic Steroidal Glycosides from the Roots of Liriope muscari . Chinese Journal of Natural Medicines 2015, 13: 461-466.

[18] Dai Y, Bao L, Huang J, Zhang M, Yu J, Zhang Y, et al.: Endothelial NMMHC IIA Dissociation from PAR1 Activates the CREB3/ARF4 Signaling in Thrombin-mediated Intracerebral Hemorrhage. Journal of Advanced Research 2025, 75: 829-842.

[19] Pirracchio R, Venkatesh B, Legrand M: Low-Dose Corticosteroids for Critically Ill Adults with Severe Pulmonary Infections: A Review. Journal of the American Medical Association 2024, 332: 318-328.

[20] Bu Y, Wu H, Deng R, Wang Y: Therapeutic Potential of SPHK1 Inhibitors Based on Abnormal Expression of SPHK1 in Inflammatory Immune Related-diseases. Frontiers in Pharmacology 2021, 12: 733387.

[21] Huang J, Pu Y, Zhang H, Xie L, He L, Zhang CL, et al.: KLF2 Mediates the Suppressive Effect of Laminar Flow on Vascular Calcification by Inhibiting Endothelial BMP/SMAD1/5 Signaling. Circulation Research 2021, 129: e87-e100.

[22] Xu S, Liu Y, Ding Y, Luo S, Zheng X, Wu X, et al.: The Zinc Finger Transcription Factor, KLF2, Protects against COVID-19 Associated Endothelial Dysfunction. Signal Transduction and Targeted Therapy 2021, 6: 266.

[23] Su T, Yang Y, Lai S, Jeong J, Jung Y, McConnell M, et al.: Single-Cell Transcriptomics Reveals Zone-specific Alterations of Liver Sinusoidal Endothelial Cells in Cirrhosis. Cellular and Molecular Gastroenterology and Hepatology 2021, 11: 1139-1161.

[24] Ding Y, Zhou Y, Ling P, Feng X, Luo S, Zheng X, et al.: Metformin in Cardiovascular Diabetology: A Focused Review of Its Impact on Endothelial Function. Theranostics 2021, 11: 9376-9396.

[25] Yuan N, Su Y, Gao Y, Yang B, Zhang T, Wang Q, et al.: Med1 Controls Thymic T-Cell Migration into Lymph Node Through Enhancer-based Foxo1-Klf2 Transcription Program. European Journal of Immunology 2024, 54: e2350887.

[26] Zhong Y, Long T, Gu CS, Tang JY, Gao LF, Zhu JX, et al.: MYH9-dependent Polarization of ATG9B Promotes Colorectal Cancer Metastasis by Accelerating Focal Adhesion Assembly. Cell Death and Differentiation 2021, 28: 3251-3269.

[27] Price DR, Garcia JGN: A Razor’s Edge: Vascular Responses to Acute Inflammatory Lung Injury/Acute Respiratory Distress Syndrome. Annual Review of Physiology 2024, 86: 505-529.

[28] Busico M, Fuentes NA, Gallardo A, Vitali A, Quintana J, Olmos M, et al.: The Predictive Validity of the Berlin Definition of Acute Respiratory Distress Syndrome for Patients with COVID-19-related Respiratory Failure Treated with High-Flow Nasal Oxygen: A Multicenter, Prospective Cohort Study. Critical Care Medicine 2024, 52: 92-101.

[29] Gorman EA, O’Kane CM, McAuley DF: Acute Respiratory Distress Syndrome in Adults: Diagnosis, Outcomes, Long-term Sequelae, and Management. Lancet 2022, 400: 1157-1170.

[30] Wang Y, Xue L, Wu Y, Zhang J, Dai Y, Li F, et al.: Ruscogenin Attenuates Sepsis-induced Acute Lung Injury and Pulmonary Endothelial Barrier Dysfunction via TLR4/Src/p120-catenin/VE-cadherin Signalling Pathway. The Journal of Pharmacy and Pharmacology 2021, 73: 893-900.

[31] Bhat OM, Mir RA, Nehvi IB, Wani NA, Dar AH, Zargar MA: Emerging Role of Sphingolipids and Extracellular Vesicles in Development and Therapeutics of Cardiovascular Diseases. International Journal of Cardiology. Heart & Vasculature 2024, 53: 101469.

[32] Weigel C, Bellaci J, Spiegel S: Sphingosine-1-phosphate and Its Receptors in Vascular Endothelial and Lymphatic Barrier Function. The Journal of Biological Chemistry 2023, 299: 104775.

[33] Ziegler AC, Gräler MH: Barrier Maintenance by S1P During Inflammation and Sepsis. Tissue Barriers 2021, 9: 1940069.

[34] Marfia G, Navone S, Guarnaccia L, Campanella R, Mondoni M, Locatelli M, et al.: Decreased Serum Level of Sphingosine-1-phosphate: A Novel Predictor of Clinical Severity in COVID-19. EMBO Molecular Medicine 2021, 13: e13424.

[35] Yang K, Sheng Y, Huang C, Jin Y, Xiong N, Jiang K, et al.: Clinical Characteristics, Outcomes, and Risk Factors for Mortality in Patients with Cancer and COVID-19 in Hubei, China: A Multicentre, Retrospective, Cohort Study. The Lancet. Oncology 2020, 21: 904-913.

[36] Thomas JM, Sudhadevi T, Basa P, Ha AW, Natarajan V, Harijith A: The Role of Sphingolipid Signaling in Oxidative Lung Injury and Pathogenesis of Bronchopulmonary Dysplasia. International Journal of Molecular Sciences 2022, 23: 1254.

[37] Tauseef M, Kini V, Knezevic N, Brannan M, Ramchandaran R, Fyrst H, et al.: Activation of Sphingosine Kinase-1 Reverses the Increase in Lung Vascular Permeability through Sphingosine-1-phosphate Receptor Signaling in Endothelial Cells. Circulation Research 2008, 103: 1164-1172.

[38] Santos AB, Carona A, Ettcheto M, Camins A, Falcão A, Fortuna A, et al.: Krüppel-like Factors: Potential Roles in Blood-Brain Barrier Dysfunction and Epileptogenesis. Acta Pharmacologica Sinica 2024, 45: 1765-1776.

[39] Parsamanesh N, Asghari A, Sardari S, Tasbandi A, Jamialahmadi T, Xu S, et al.: Resveratrol and Endothelial Function: A Literature Review. Pharmacological Research 2021, 170: 105725.

[40] Lee HY, Youn SW, Cho HJ, Kwon YW, Lee SW, Kim SJ, et al.: FOXO1 Impairs Whereas Statin Protects Endothelial Function in Diabetes through Reciprocal Regulation of Kruppel-like Factor 2. Cardiovascular Research 2013, 97: 143-152.

[41] Li Y, Liu X, Lin X, Zhao M, Xiao Y, Liu C, et al.: Chemical Compound Cinobufotalin Potently Induces FOXO1-stimulated Cisplatin Sensitivity by Antagonizing its Binding Partner MYH9. Signal Transduction and Targeted Therapy 2019, 4: 48.

[42] Essers MA, Weijzen S, de Vries-Smits AM, Saarloos I, de Ruiter ND, Bos JL, et al.: FOXO Transcription Factor Activation by Oxidative Stress Mediated by the Small GTPase Ral and JNK. The EMBO Journal 2004, 23: 4802-4812.

[43] Vicente-Manzanares M, Ma X, Adelstein RS, Horwitz AR: Non-muscle Myosin II Takes Centre Stage in Cell Adhesion and Migration. Nature Reviews Molecular Cell Biology 2009, 10: 778-790.

[44] Zhao X, Gan L, Pan H, Kan D, Majeski M, Adam SA, et al.: Multiple Elements Regulate Nuclear/cytoplasmic Shuttling of FOXO1: Characterization of Phosphorylation- and 14-3-3-dependent and -independent Mechanisms. The Biochemical Journal 2004, 378: 839-849.